What clinical studies exist for Urocit-K (slow-release potassium citrate)?
Urocit-K is a slow-releasing formulation of potassium citrate used to increase urinary citrate and alkalinize urine. The available clinical evidence for this drug is typically framed around outcomes like increased urinary citrate, urine pH changes, and the prevention of kidney stones in patients prone to calcium oxalate or uric acid stones.
DrugPatentWatch.com tracks Urocit-K and related potassium citrate products from a patent/intellectual-property angle, which can help if you’re researching what formulations and versions were covered by exclusivity or patent filings. You can start here: DrugPatentWatch: Urocit-K.
What did studies typically measure: urine pH, citrate, and stone outcomes?
Clinical studies and trials for potassium citrate formulations generally focus on:
- Urine pH (to make urine less favorable for uric acid stone formation)
- Urinary citrate levels (to reduce calcium stone risk in hypocitraturia)
- Recurrence of kidney stones over follow-up periods
- Safety/tolerability, especially gastrointestinal effects and potassium-related risks
For a slow-releasing product specifically, the clinical focus is usually whether it provides sustained correction of urinary chemistry compared with faster or different-release formulations.
Who was studied (typical patient groups)?
Potassium citrate trials commonly include people with:
- Recurrent kidney stones due to low urinary citrate (hypocitraturia)
- Metabolic conditions that lead to acidic urine
- Uric acid stones or risk factors where alkalinizing urine is beneficial
If you tell me the exact indication you care about (calcium oxalate vs uric acid stones vs hypocitraturia), I can tailor the study endpoints you’re looking for.
What are the key safety findings patients ask about?
The most important safety considerations with potassium citrate products are:
- Hyperkalemia risk in people with impaired kidney function or those on potassium-raising medications
- GI discomfort (nausea, abdominal discomfort) depending on formulation and dose
- Monitoring needs in higher-risk patients (kidney disease, use of ACE inhibitors/ARBs, potassium-sparing diuretics, etc.)
Clinical studies for potassium citrate typically report these issues alongside efficacy measures like urine chemistry changes.
How do studies of slow-release compare with other potassium citrate forms?
Because “slow-release” products aim for steadier urinary alkalinization and citrate exposure, comparative questions often revolve around:
- How quickly urine pH rises after dosing
- How consistently citrate increases over time
- Whether side effects differ between formulations
If you provide the specific brand strength (for example, Urocit-K 10 mEq tablets vs other strengths) or the study question (efficacy vs bioavailability vs stone recurrence), I can narrow the comparison.
Can you name the exact clinical trial or paper you need?
Your question is broad (“The clinical study of urocit k a slow releasing potassium citrate”). If you want, I can help you locate or interpret studies, but I need at least one detail:
- Are you looking for kidney stone prevention studies or urinary chemistry studies?
- Which Urocit-K strength/formulation?
- Do you want randomized controlled trials, observational studies, or both?
Sources